NovoCure Limited
$12.67
▼
-2.68%
2026-04-21 08:31:00
www.novocure.com
NMS: NVCR
Explore NovoCure Limited stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.44 B
Current Price
$12.67
52W High / Low
$20.06 / $9.82
Stock P/E
—
Book Value
$3.03
Dividend Yield
—
ROCE
-26.47%
ROE
-38.89%
Face Value
—
EPS
$-1.22
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
1,605
Beta
0.82
Debt / Equity
72.94
Current Ratio
2.9
Quick Ratio
2.71
Forward P/E
-9.08
Price / Sales
1.84
Enterprise Value
$1 B
EV / EBITDA
-7.43
EV / Revenue
1.53
Rating
Buy
Target Price
$25.07
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Viemed Healthcare, Inc. | $9.66 | 24.97 | $372.9 M | — | 13.1% | 11.11% | $10.06 / $5.93 | $3.72 |
| 2. | Neogen Corporation | $9.63 | — | $2.08 B | — | -0.05% | -25.57% | $11.43 / $4.32 | $9.68 |
| 3. | Pulsenmore Ltd. | $3.33 | — | $72.38 M | — | -33.09% | -17.62% | $1,468 / $1,000 | — |
| 4. | NeuroPace, Inc. | $16.53 | — | $545.07 M | — | -18.62% | -1.59% | $18.98 / $7.56 | $0.57 |
| 5. | Phaos Technology Holdings (Caym | $1.95 | — | — | — | 214.51% | -10.73% | $7.39 / $0.53 | $-0.06 |
| 6. | Biomerica, Inc. | $2.18 | — | $6.74 M | — | -122.16% | -84.3% | $4.6 / $1.87 | $1.5 |
| 7. | Stryker Corporation | $334.05 | 39.78 | $127.84 B | 1.04% | 12.63% | 15.08% | $404.87 / $319.32 | $58.61 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 174.35 M | 167.2 M | 158.81 M | 154.99 M | 161.27 M |
| Operating Profit | -40.39 M | -36.02 M | -39.52 M | -37.87 M | -63.3 M |
| Net Profit | -24.5 M | -37.27 M | -40.14 M | -34.32 M | -65.92 M |
| EPS in Rs | -0.22 | -0.33 | -0.35 | -0.3 | -0.58 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 655.35 M | 605.22 M | 509.34 M | 537.84 M |
| Operating Profit | -153.8 M | -170.5 M | -232.87 M | -89.52 M |
| Net Profit | -136.23 M | -168.63 M | -207.04 M | -92.53 M |
| EPS in Rs | -1.2 | -1.48 | -1.82 | -0.81 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 804.33 M | 1.24 B | 1.15 B | 1.19 B |
| Total Liabilities | 463.86 M | 880.61 M | 783.63 M | 750.48 M |
| Equity | 340.47 M | 360.18 M | 362.5 M | 441.17 M |
| Current Assets | 646.73 M | 1.11 B | 1.03 B | 1.11 B |
| Current Liabilities | 223.23 M | 756.39 M | 179.12 M | 158.78 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -49.03 M | -26.37 M | -73.34 M | 30.79 M |
| Investing CF | 437.28 M | -140.24 M | 184.15 M | -139.96 M |
| Financing CF | -451.34 M | 90.31 M | 15.79 M | 15.49 M |
| Free CF | -75.68 M | -69.22 M | -100.43 M | 9.43 M |
| Capex | -26.65 M | -42.85 M | -27.09 M | -21.36 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 8.28% | 18.82% | -5.3% | — |
| Earnings Growth % | 19.21% | 18.55% | -123.75% | — |
| Profit Margin % | -20.79% | -27.86% | -40.65% | -17.2% |
| Operating Margin % | -23.47% | -28.17% | -45.72% | -16.64% |
| Gross Margin % | 74.54% | 77.33% | 74.81% | 78.64% |
| EBITDA Margin % | -15.96% | -18.11% | -34.84% | -12.62% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.